Clinical TrialJul 13, 2026, 04:07 PM
Clearmind Shares Promising Insights from CMND-100 First-in-Human Trial
AI Summary
Clearmind Medicine Inc. provided an update on its ongoing CMND-100 first-in-human clinical trial for Alcohol Use Disorder (AUD). Principal investigators from Yale School of Medicine and Johns Hopkins University shared positive early experiences, highlighting CMND-100's non-hallucinogenic profile and promising safety. The company noted the potential for broader applications of MEAI beyond AUD.
Key Highlights
- Principal investigators highlighted positive early experience with CMND-100 for Alcohol Use Disorder.
- CMND-100's non-hallucinogenic profile allows for a simpler, more accessible treatment model.
- Reduced dependence on subjective psychedelic experiences improves assessment of pharmacological effects.
- Recruitment for the trial has progressed well despite strict eligibility criteria.
- Promising early safety profile observed with no meaningful adverse effects or cardiac safety concerns.
- Trial led by investigators from Yale School of Medicine and Johns Hopkins University.
- High potential for broader applications of MEAI beyond Alcohol Use Disorder.
Price Impact
More from CMND